Li ZH, Ma YJ, Jia ZH, Weng YY, Zhang P, Zhu SJ, Wang F. Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer. World J Clin Cases 2022; 10(27): 9703-9713 [PMID: 36186177 DOI: 10.12998/wjcc.v10.i27.9703]
Corresponding Author of This Article
Fang Wang, MD, Chief Doctor, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, No. 6 Huajiadi Road, Beijing 100102, China. wf074500@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Zhong-Hui Li, Yin-Jie Ma, Shi-Jie Zhu, Fang Wang, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China
Zong-Hang Jia, Department of Oncology, Shandong University of Traditional Chinese Medicine, Jinan 250022, Shandong Province, China
Yue-Yan Weng, Department of Acupuncture and Moxibustion, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China
Ping Zhang, Department of Pathology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China
Author contributions: Li ZH performed literature search, collected the data, statistical analysis and wrote the manuscript; Ma YJ designed the study, performed literature search, collected the data, performed statistical analysis and wrote the manuscript; Li ZH and Ma YJ have contributed equally to this work; Jia ZH performed statistical analysis, revised the manuscript and provided critical opinion; Weng YY analyzed and interpreted the data; Zhang P, Wang F, and Zhu SJ provided critical opinion and revised the manuscript; Wang F provided critical opinion, participated in literature search, and revised the manuscript; Li ZH and Ma YJ have contributed equally to this work. all authors approved the final manuscript.
Conflict-of-interest statement: The authors declare that there is no potential conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fang Wang, MD, Chief Doctor, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, No. 6 Huajiadi Road, Beijing 100102, China. wf074500@163.com
Received: April 3, 2022 Peer-review started: April 3, 2022 First decision: May 11, 2022 Revised: May 17, 2022 Accepted: August 15, 2022 Article in press: August 15, 2022 Published online: September 26, 2022 Processing time: 165 Days and 22 Hours
ARTICLE HIGHLIGHTS
Research background
Pancreatic cancer is a highly malignant disease. Gemcitabine plus albumin combined with nab-paclitaxel (GA) is a common first-line treatment regimen for metastatic pancreatic cancer, and there is currently much clinical controversy about the effectiveness of adding a novel targeted agent to this regimen.
Research motivation
An analysis of studies using GA in combination with targeted drug regimens for the treatment of metastatic pancreatic cancer is presented to discuss its efficacy and safety.
Research objectives
Analysis comparing the effectiveness and safety of GA combined with targeted drug regimens and GA regimens.
Research methods
Eligible randomized controlled trials related to GA and GA + targeted agents were searched in PubMed, EMBASE and Cochrane Library, and overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and toxicity were pooled and finally analyzed by Stata version 15.1. In addition, use Reference Citation Analysis (https://www.referencecitationanalysis.com/) to collect the latest related literature to improve the latest cutting-edge research results.
Research results
There were no significant differences in PFS, OS,and ORR between GA + targeted drugs and GA. Grade 3/4 toxicity, such as fatigue, anemia, vomiting and neutropenia, was not significantly different between the two groups, and the incidence of grade 3/4 diarrhea was significantly increased by GA + targeted agents.
Research conclusions
Adding a novel targeted agent to the GA regimen did not improve survival in patients with metastatic pancreatic cancer.
Research perspectives
There is a gap between clinical and theoretical. Theoretically, new targeted drugs will improve the therapeutic effect but not the same result in the clinic.
